Cargando…
Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition
The standard front-line treatment for pleural mesothelioma (PM) is pemetrexed-based chemotherapy, whose major target is thymidylate synthase (TS). In several cancer models, miR-215 and miR-375 have been shown to target TS, while information on these miRNAs in PM are still limited although suggest th...
Autores principales: | Napoli, Francesca, Rapa, Ida, Izzo, Stefania, Rigutto, Angelica, Libener, Roberta, Riganti, Chiara, Bironzo, Paolo, Taulli, Riccardo, Papotti, Mauro, Volante, Marco, Scagliotti, Giorgio, Righi, Luisella |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343276/ https://www.ncbi.nlm.nih.gov/pubmed/35461395 http://dx.doi.org/10.1007/s00428-022-03321-8 |
Ejemplares similares
-
Correction to: Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition
por: Napoli, Francesca, et al.
Publicado: (2022) -
Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma
por: Napoli, Francesca, et al.
Publicado: (2021) -
Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma
por: Anobile, Dario P., et al.
Publicado: (2021) -
SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma
por: Salaroglio, Iris Chiara, et al.
Publicado: (2022) -
Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma
por: Villanova, Tania, et al.
Publicado: (2019)